Ron M. Herings, PharmD, PhD, FISPE

Director
PHARMO Institute, Netherlands

PHARMO Institute of Drug Outcomes Research (Contracted Research, R Herings is an employees of the PHARMO Institute for Drug Outcomes Research. This independent research institute performs financially supported studies for government and related healthcare authorities and pharmaceutical companies)

Poster(s):

• (P-065) Safety of Rivaroxaban in First-time Users Treated for Deep Vein Thrombosis and Pulmonary Embolism

• (P-250) Lessons from a Post-authorisation Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Practice in Four Countries

• (P-251) Anti-osteoporosis Treatment After a Major Osteoporotic Fracture Is Often Lacking

• (P-252) Safety and Effectiveness of Rivaroxaban in First-time Users with Non-valvular Atrial Fibrillation in Routine Practice

• (P-314) Time Trends in Patient Characteristics of New Rivaroxaban (RVX) Users with Atrial Fibrillation (AF) Across Four Countries

• (P-377) Users of Biologics for Crohn’s Disease and Ulcerative Colitis in the Netherlands

• (P-515) Factors Predictive of Treatment Success of Novel Disease-modifying Anti-rheumatic Drugs (DMARDS) in Patients with Inflammatory Arthritis

• (P-567) SIGMA Consortium: A New Era of Collaboration to Study the Safety and Effectiveness of Medical Interventions

• (P-568) Limited Time Interval Between Symptomatic Presentation in Primary Care and Colorectal Cancer Diagnosis